natgillin/translations-raw huggingface dataset:
This medicinal product must not be mixed with other medicinal products.
To zdravilo se ne sme mešati z drugimi zdravili.
Fully supplemented Patients
Bolniki s popolnim bolniki dopolnjevanjem
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines, including medicine for pain or inflammation (swelling), such as medicines called “nonsteroidal anti-inflammatory drugs” (NSAIDs), including medicines purchased without a doctor's prescription (such as ibuprofen).
Obvestite zdravnika ali farmacevta, če jemljete, ste pred kratkim jemali ali pa boste morda začeli jemati katera koli druga zdravila, vključno z zdravili proti bolečinam ali vnetju (oteklinam), denimo zdravila, imenovana “nesteroidna protivnetna zdravila” (NSAID), vključno z zdravili, ki ste jih dobili brez recepta (kot npr. ibuprofen).
The dose of Armisarte is 500 milligrams for every square metre of your body's surface area.
Odmerek zdravila Armisarte je 500 miligramov za vsak kvadratni meter površine vašega telesa.
Detailed information on this medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu.
Podrobne informacije o tem zdravilu so dostopne na spletni strani Evropske agencije za zdravila http://www.ema.europa.eu.
11 Ion Mihalache Blvd. 011171 Bucharest Romania
11 Ion Mihalache Blvd. 011171 Bukarešta Romunija
Store and transport refrigerated (2°C to 8°C).
Zdravilo shranjujte in prevažajte na hladnem (2°C to 8°C).
Your doctor will discuss with you the potential risk of taking Armisarte during pregnancy.
Z zdravnikom se pogovorite o možnem tveganju pri prejemanju zdravila Armisarte v času nosečnosti.
Upon recovery patients should be retreated using the guidelines in Tables 1, 2 and 3, which are applicable for pemetrexed used as a single agent or in combination with cisplatin.
Po okrevanju bolnike ponovno zdravimo z uporabo smernic v Preglednicah 1, 2 in 3, ki veljajo za pemetreksed, če jo uporabljamo kot edino učinkovino ali v kombinaciji s cisplatinom.
This routinely involves blood tests, including checks on your liver and kidney function.
To rutinsko vključuje preiskave krvi, vključno s preverjanjem delovanja vaših jeter in ledvic.
Other medicines and Armisarte
Druga zdravila in zdravilo Armisarte
75% of previous dose
75 % predhodnega odmerka
**In the pemetrexed/cisplatin arm, randomized and treated (N=225) and fully supplemented (N=167)
**V veji zdravljenja s pemetreksedom/cisplatinom, randomizirani in zdravljeni (N = 225) ter s popolnim dopolnjevanjem (N = 167).
This medicine is for single use only; any unused solution must be disposed of in accordance with local requirements.
To zdravilo je namenjeno samo enkratni uporabi, morebitno neporabljeno raztopino je treba odstraniti v skladu z lokalnimi predpisi.
75% of previous dose (both pemetrexed and cisplatin)
75 % predhodnega odmerka (obeh pemetrekseda in cisplatina)
Before each infusion you will have samples of your blood taken to evaluate if you have sufficient kidney and liver function and to check that you have enough blood cells to receive Armisarte.
Pred vsako infuzijo vam bomo odvzeli vzorce krvi za vrednotenje delovanja vaših ledvic in jeter ter oceno, ali imate dovolj krvnih celic za prejemanje zdravila Armisarte.
Trometamol is incompatible with cisplatin resulting in degradation of cisplatin.
Trometamol je inkompatibilen s cisplatinom in povzroči razgradnjo cisplatina.
At the time of this final survival analysis, 28.7% of patients were alive or lost to follow up on the pemetrexed arm versus 21.7% on the placebo arm.
V času te končne analize preživetja je bilo živih ali ni bilo na voljo za nadaljnje spremljanje 28,7 % bolnikov v kraku pemetrekseda v primerjavi z 21,7 % v kraku s placebom.
Contents of the pack and other information What Armisarte contains
Vsebina pakiranja in dodatne informacije Kaj vsebuje zdravilo Armisarte
The pharmacokinetic properties of pemetrexed following single-agent administration have been evaluated in 426 cancer patients with a variety of solid tumours at doses ranging from 0.2 to 838 mg/m2 infused over a 10 minute period.
Farmakokinetične lastnosti pemetrekseda po dajanju ene učinkovine so vrednotili pri 426 bolnikih z različnimi malignimi trdnimi tumorji v razponu odmerkov od 0,2 do 838 mg/m2, infundiranih v 10 minutah.
< 1/100), Rare (≥ 1/10,000 to < 1/1,000), Very rare (< 1/10,000) and not known (cannot be estimated from available data).
Pogostnosti so določene kot: zelo pogosto (≥ 1/10), pogosto (≥ 1/100 do < 1/10), občasno (≥1/1.000 do < 1/100), redko (≥ 1/10.000 do < 1/1.000), zelo redko (< 1/10.000) in neznana pogostnost (ni mogoče oceniti iz razpoložljivih podatkov).
Any unused medicinal product or waste material must be disposed of in accordance with local requirements.
Neuporabljeno zdravilo ali odpadke je treba zavreči v skladu z lokalnimi zahtevami.
Name and address of the manufacturers responsible for batch release PLIVA CROATIA Ltd.
Ime in naslov izdelovalca (izdelovalcev), odgovornega (odgovornih) za sproščanje serij PLIVA CROATIA Ltd.
If you have been recently vaccinated, please tell your doctor, as this can possibly cause bad effects with Armisarte.
Če ste bili nedavno cepljeni, prosimo, povejte to zdravniku saj lahko to ob jemanju zdravila Armisarte povzroča škodljive učinke.
When using Armisarte in combination with cisplatin:
Kadar uporabljamo zdravilo Armisarte v kombinaciji s cisplatinom:
****Combined term includes increased serum/blood creatinine, decreased glomerular filtration rate, renal failure and renal/genitourinary- other.
**** Skupni izraz vključuje povišan kreatinin v serumu/krvi, znižano stopnjo glomerulne filtracije, ledvično odpoved in ledvice/sečila - drugo.
Armisarte is a medicine used in the treatment of cancer.
Zdravilo Armisarte uporabljamo pri zdravljenju raka.
If you currently have or have previously had problems with your kidneys, talk to your doctor or hospital pharmacist as you may not be able to receive Armisarte.
Če imate ali ste imeli težave z ledvicami, se pogovorite z zdravnikom ali bolnišničnim farmacevtom, ker morda ne boste mogli prejeti zdravila Armisarte.
The use of Armisarte should be avoided during pregnancy.
Uporabi zdravila Armisarte med nosečnostjo se izogibamo.
Cisplatin is also given by infusion into one of your veins, and is given approximately 30 minutes after the infusion of Armisarte has finished.
Cisplatin tudi dajemo v obliki infuzije v veno, približno 30 minut po zaključku infuzije zdravila Armisarte.
Progression free survival (months)
Preživetje brez napredovanja (meseci)
Pharmacotherapeutic group: antineoplastic agents, folic acid analogues, ATC code: L01BA04.
Farmakoterapevtska skupina: Analogi folne kisline, Oznaka ATC: L01BA04
If you have an accumulation of fluid around your lungs, your doctor may decide to remove the fluid before giving you Armisarte.
Če se vam okrog pljuč nabira tekočina, se bo zdravnik morda odločil tekočino pred dajanjem zdravila Armisarte odstraniti.
Common Pain Oedema Renal Disorders Common Renal disorders**** Abbreviations: ALT = alanine aminotransferase; AST = aspartate aminotransferase; CTCAE = Common Terminology Criteria for Adverse Event; NCI = National Cancer Institute; SGOT=serum glutamic oxaloacectic aminotransferase; SGPT=serum glutamic pyruvic aminotransferase.
Okrajšave: ALT = alaninska aminotransferaza; AST = aspartatna aminotransferaza; CTCAE = običajni terminološki kriteriji za neželene učinke; NCI = nacionalni inštitut za rakava obolenja; SGOT = serumska glutamat oksalocetna aminotransferaza; SGPT = serumska glutamat piruvična aminotransferaza.
You must contact your doctor immediately if you notice any of the following: - Fever or infection (common): if you have a temperature of 38°C or greater, sweating or other signs of infection(since you might have less white blood cells than normal which is very common).
Če opazite katerega od spodaj naštetih učinkov, morate nemudoma poklicati zdravnika: - Povišana telesna temperatura ali okužba (pogosto): če se pojavi temperatura 38 ºC ali višja, znojenje ali drugi znaki okužbe (ker imate lahko manj belih krvničk kot normalno, kar je zelo pogosto).
Statistically significant for noninferiority, with the entire confidence interval for HR well below the 1.17645 noninferiority margin (p <0.001).
aStatistično pomembna za prednost, s celotnim intervalom zaupanja za RT znatno pod 1,17645 mejo prednosti (p
Treatment with pemetrexed should be discontinued if a patient experiences any haematologic or nonhaematologic Grade 3 or 4 toxicity after 2 dose reductions or immediately if Grade 3 or 4 neurotoxicity is observed.
Zdravljenje s pemetreksedom moramo prekiniti, če bolnik izkusi kakršnokoli hematološko ali nehematološko toksičnost stopnje 3 ali 4 po 2 znižanjih odmerka ali nemudoma, če opazimo nevrološko toksičnost stopnje 3 ali 4.
The printed package leaflet of the medicinal product must state the name and address of the manufacturer responsible for the release of the concerned batch.
V natisnjenem navodilu za uporabo mora biti naveden izdelovalec odgovoren za sproščanje zadevne serije.
What you need to know before you use Armisarte Do not use Armisarte
Kaj morate vedeti, preden boste vzeli zdravilo Armisarte Ne uporabljajte zdravila Armisarte:
4 ml vial 20 ml vial 34 ml vial 40 ml vial
4 ml viala 20 ml viala 34 ml viala 40 ml viala
Men are advised not to father a child during and up to 6 months following treatment with Armisarte and should therefore use effective contraception during treatment with Armisarte and for up to 6 months afterwards.
Moškim odsvetujemo, da bi v času zdravljenja z zdravilom Armisarte ter do 6 mesecev po zdravljenju s tem zdravilom spočeli otroka, zato naj v času zdravljenja z zdravilom Armisarte ter do 6 mesecev po zdravljenju s tem zdravilom uporabljajo učinkovito kontracepcijo.
If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would not be longer than 24 hours at 2°C to 8°C, unless dilution has taken place in controlled and validated aseptic conditions.
Če zdravila, pripravljenega za uporabo, ne uporabimo takoj, je za čase shranjevanja in pogoje pred uporabo odgovoren uporabnik, in naj bi ne presegali 24 ur pri 2 do 8°C, razen če je priprava potekala v kontroliranih in validiranih aseptičnih pogojih.
What Armisarte is and what it is used for What you need to know before you use Armisarte How to use Armisarte
Kaj je zdravilo Armisarte in za kaj ga uporabljamo Kaj morate vedeti, preden boste uporabili zdravilo Armisarte Kako uporabljati zdravilo Armisarte Možni neželeni učinki
Median overall survival (months) (95% CI) Log Rank p-value* Median time to tumour progression (months) (95% CI) Log Rank p-value* Time to treatment failure (months) (95% CI) Log Rank p-value* Overall response rate** (95% CI) Fisher's exact p-value* Abbreviation: CI = confidence interval *p-value refers to comparison between arms.
Mediana skupnega preživetja (meseci) (95 % IZ) Log Rank p-vrednost* Mediana časa do napredovanja tumorja (meseci) (95 % IZ) Log Rank p-vrednost* Čas do neuspeha zdravljenja (meseci) (95 % IZ) Log Rank p-vrednost* Skupna stopnja odziva** (95 % IZ) Fisherjeva točna p-vrednost* Okrajšava: IZ = interval zaupanja *p-vrednost se nanaša na primerjavo med vejama zdravljenja.
A hospital pharmacist, nurse or doctor will have mixed the Armisarte concentrate with 5% glucose solution for injection before it is given to you.
Bolnišnični farmacevt, medicinska sestra ali zdravnik bo koncetrat zdravila Armisarte, preden ga boste prejeli, zmešal z 5 % raztopino glukoze za injiciranje.
EU/1/15/1063/001 4 ml vial EU/1/15/1063/002 20 ml vial EU/1/15/1063/004 34 ml vial EU/1/15/1063/003 40 ml vial
EU/1/15/1063/001 4 ml viala EU/1/15/1063/002 20 ml viala EU/1/15/1063/004 34 ml viala EU/1/15/1063/003 40 ml viala
Intravenous lines should be flushed after administration of Armisarte.
Intravenske linije je potrebno po uporabi zdravila Armisarte sprati.
Corticosteriods: your doctor will prescribe you steroid tablets (equivalent to 4 milligram of dexamethasone twice a day) that you will need to take on the day before, on the day of, and the day after Armisarte treatment.
Kortikosteroidi: zdravnik vam bo predpisal tablete steroidov (ustrezno 4 miligramom deksametazona dvakrat dnevno), ki jih boste morali jemati dan pred zdravljenjem z zdravilom Armisarte, na dan zdravljenja in na dan po zdravljenju z zdravilom Armisarte.
Armisarte can be prescribed to you if you have lung cancer at an advanced stage if your disease has responded to treatment or it remains largely unchanged after initial chemotherapy.
Zdravnik vam lahko predpiše zdravilo Armisarte, če imate pljučni rak v napredovalem stadiju in če se vaša bolezen odziva na zdravljenje oz. če po začetni kemoterapiji ostaja večinoma nespremenjena.
Each pack of Armisarte contains one vial.
Eno pakiranje zdravila Armisarte vsebuje eno vialo.
ANNEX IV SCIENTIFIC CONCLUSIONS AND GROUNDS FOR THE VARIATION TO THE TERMS OF THE MARKETING AUTHORISATION(S)
ZNANSTVENI ZAKLJUČKI IN PODLAGA ZA SPREMEMBO POGOJEV DOVOLJENJ(A)
Armisarte is also given in combination with cisplatin for the initial treatment of patients with advanced stage of lung cancer.
Zdravilo Armisarte se daje tudi v kombinaciji s cisplatinom, za začetno zdravljenje bolnikov z napredovalim stadijem pljučnega raka.
Keep the vial in the outer carton to protect from light.
Vialo shranjujte v zunanji škatli za zagotovitev zaščite pred svetlobo.
Vitamin supplementation: your doctor will prescribe you oral folic acid (vitamin) or a multivitamin containing folic acid (350 to 1000 micrograms) that you must take once a day while you are receiving Armisarte.
Dopolnjevanje vitaminov: zdravnik vam bo predpisal peroralno folno kislino (vitamin) ali multivitaminski pripravek, ki vsebuje folno kislino (350 do 1000 mikrogramov), ki ga boste morali med prejemanjem zdravila Armisarte jemati enkrat dnevno.
The appropriate volume of pemetrexed concentrate must be diluted to 100 ml with 5% glucose solution and administered as an intravenous infusion over 10 minutes.
Ustrezen volumen koncentrata pemetrekseda je potrebno razredčiti do 100 ml s 5 % raztopino glukoze in uporabiti kot intravensko infuzijo, ki traja 10 minut.
Armisarte must only be diluted with 5% glucose solution, without preservative.
Zdravilo Armisarte je potrebno razredčiti s 5 % raztopino glukoze brez konzervansa.
Limited clinical data from a separate randomized, Phase 3, controlled trial, suggest that efficacy data (overall survival, progression free survival) for pemetrexed are similar between patients previously pre-treated with docetaxel (n = 41) and patients who did not receive previous docetaxel treatment (n = 540).
Omejeni klinični podatki iz ločeno randomiziranih, kontroliranih preskušanj faze 3, nakazujejo, da so podatki o učinkovitosti (skupno preživetje, preživetje brez napredovanja) za pemetreksed podobni med bolniki, ki so bili predhodno zdravljeni z doksatakselom (n = 41) in bolniki, ki niso prejeli predhodnega zdravljenja z doksatakselom (n = 540).
If you have had or are going to have radiation therapy, please tell your doctor, as there may be an early or late radiation reaction with Armisarte.
Če ste imeli ali če boste imeli zdravljenje z obsevanjem, prosimo, povejte to zdravniku, saj ob jemanju zdravila Armisarte lahko pride do zgodnje ali pozne reakcije na obsevanje.
Armisarte is also a treatment for patients with advanced stage of lung cancer whose disease has progressed after other initial chemotherapy has been used.
Zdravilo Armisarte je namenjeno tudi zdravljenju bolnikov z napredovalim stadijem pljučnega raka, katerih bolezen se širi po tem, ko je bila že uporabljena druga začetna kemoterapija.
Clinically relevant Grade 3 and Grade 4 laboratory toxicities were similar between integrated Phase 2 results from three single agent pemetrexed studies (n=164) and the Phase 3 single agent pemetrexed study described above, with the exception of neutropenia (12.8 % versus 5.3 %, respectively) and alanine aminotransferase elevation (15.2 % versus 1.9 %, respectively).
Klinično pomembne laboratorijske toksičnosti stopenj 3 in 4 so bile podobne pri integriranih rezultatih faze 2 treh študij pemetrekseda kot edine učinkovine (n = 164) in faze 3 študije pemetrekseda kot edine učinkovine, opisane zgoraj, z izjemo nevtropenije (12,8 % oziroma 5,3 %) in povišanja alaninske aminotransferaze (15,2 % oziroma 1,9 %).
During the study, low-dose folic acid and vitamin B12 supplementation was introduced to patients therapy to reduce toxicity.
V trajanju študije so bolnikom uvedli v terapijo nizke odmerke dopolnilne folne kisline in vitamina B12, za zmanjšanje toksičnosti.
For storage conditions after dilution of the medicinal product, see section 6.3.
Za pogoje shranjevanja po razredčitvi zdravila glejte poglavje 6.3.
You will also receive an injection of vitamin B12 (1000 micrograms) in the week before administration of Armisarte and then approximately every 9 weeks (corresponding to 3 courses of Armisarte treatment).
V tednu pred dajanjem zdravila Armisarte boste prejeli tudi injekcijo vitamina B12 (1000 mikrogramov), nato pa še približno na vsakih 9 tednov (ustrezno 3 ciklusom zdravljenja z zdravilom Armisarte).
Pemetrexed belongs to a group of medicines known as folic acid analogues and disrupts processes that are essential for cells to divide.
Pemetreksed sodi v skupino zdravil, znanih kot analogi folne kisline, in ruši procese, ki so ključni za podvajanje celic.
Armisarte contains trometamol as an excipient.
Armisarte kot pomožno snov vsebuje trometamol.
What Armisarte looks like and contents of the pack
Izgled zdravila Armisarte in vsebina pakiranja
Colourless glass vial (type I) with type I rubber (bromobutyl) serum stopper and an aluminium cap with polypropylene disk.
Brezbarvna steklena viala (tip I) z gumijastim (bromobutil) serumskim zamaškom tipa I in aluminijasto zaporko s polipropilensko ploščico.
Armisarte 25 mg/ml concentrate for solution for infusion will always be given to you by a healthcare professional.
Zdravilo Armisarte 25 mg/ml koncentrat za raztopino za infundiranje vam bo vedno dal zdravstveni delavec.
Armisarte is given in combination with cisplatin, another anti-cancer medicine, as treatment for malignant pleural mesothelioma, a form of cancer that affects the lining of the lung, to patients who have not received prior chemotherapy.
Zdravilo Armisarte dajemo v kombinaciji s cisplatinom, drugim zdravilom proti raku, za zdravljenje malignega plevralnega mezotelioma, vrste raka, ki prizadene vrhnjo plast pljuč, bolnikom, ki pred tem še niso prejemali kemoterapije.
100% of previous dose
100 % predhodnega odmerka 100 % predhodnega odmerka
You will always receive Armisarte by infusion into one of your veins.
Zdravilo Armisarte boste vedno prejeli v obliki infuzije v veno.
Less toxicity and reduction in Grade 3/4 haematologic and non-haematologic toxicities such as neutropenia, febrile neutropenia and infection with Grade 3/4 neutropenia were reported when pretreatment with folic acid and vitamin B12 was administered.
Poročali so o povprečno manjši toksičnosti ter znižanju hematoloških in nehematoloških toksičnosti stopnje 3/4, denimo nevtropeniji, febrilni nevtropeniji ter okužbi z nevtropenijo stopnje 3/4, kadar so pred zdravljenjem dajali folno kislino in vitamin B12.
For instructions on dilution of Armisarte before administration, see section 6.6.
Za informacije o redčenju zdravila Armisarte pred uporabo glejte poglavje 6.6.
Armisarte should be administered as an intravenous infusion over 10 minutes on the first day of each 21-day cycle.
Zdravilo Armisarte se daje kot 10-minutna intravenska infuzija prvi dan vsakega 21-dnevnega ciklusa.
Armisarte concentrate for solution for infusion (sterile concentrate) is a clear, colourless to slightly yellowish or yellow-greenish solution.
Zdravilo Armisarte koncentrat za raztopino za infundiranje (sterilni koncentrat) je bistra, brezbarvna do rahlo rumenkasta ali rumeno-zelenkasta raztopina.
1 x 4 ml vial (100 mg/4 ml) 1 x 20 ml vial (500 mg/20 ml) 1 x 34 ml vial (850 mg/34 ml) 1 x 40 ml vial (1000 mg/40 ml)
Velikost pakiranj 1 x 4 ml viala (100 mg/4 ml) 1 x 20 ml viala (500 mg/20 ml) 1 x 34 ml viala (850 mg/34 ml) 1 x 40 ml viala (1000 mg/40 ml)
Not known (frequency cannot be estimated from the available data) - Lower limb swelling with pain and redness - Inflammation of the skin, mainly of the lower limb with swelling, pain and redness - Increased urine output - Thirst and increased water consumption - Hypernatraemia - increased sodium in blood
Neznana pogostnost (pogostnosti ni mogoče oceniti iz razpoložljivih podatkov) - otekanje spodnjih okončin z bolečino in pordelostjo - vnetje kože, večinoma spodnjih okončin, z otekanjem, bolečino in pordelostjo - povečano izločanje urina - zeja in povečano pitje vode
Like other chemotherapy medicines Armisarte is not recommended with live attenuated vaccines.
Tako kot pri ostalih kemoterapevtikih je odsvetovana sočasna uporaba zdravila Armisarte in živih oslabljenih cepiv.
Gemcitabine/ cisplatin (N=830)
Gemcitabin/cisplatin N = 830
Excipients: trometamol, anhydrous citric acid, methionine and water for injections.
Pomožne snovi: trometamol, brezvodna citronska kislina, metionin in voda za injekcije.
Chemical and physical in-use stability of infusion solution of pemetrexed was demonstrated for 3 days at room temperature and 21 days at refrigerated temperature.
Kemijsko in fizikalno obstojnost raztopine pemetrekseda za infundiranje so pokazali za 3 dni na sobni temperaturi in 21 dni pri temperaturah v hladilniku.
How to store Armisarte
Kako jemati zdravilo Armisarte
Infusion Solution: Chemical and physical in-use stability of infusion solution of pemetrexed was demonstrated for 3 days at room temperature and 21 days at refrigerated temperature.
Raztopina za infundiranje: Kemijsko in fizikalno obstojnost raztopin pemetrekseda za infundiranje so pokazali za 3 dni na sobni temperaturi in 21 dni pri temperaturah v hladilniku.
There is no relevant use of Armisarte in the paediatric population
Zdravilo Armisarte ni namenjeno za uporabo pri pediatrični populaciji.
Taking into account the PRAC Assessment Report on the PSUR(s) for pemetrexed, the scientific conclusions of CHMP are as follows:
Znanstveni zaključki Upoštevajoč poročilo Odbora za oceno tveganja na področju farmakovigilance (PRAC) o oceni rednih posodobljenih poročil o varnosti zdravila (PSUR) za pemetreksed je Odbor za zdravila za uporabo v humani medicini (CHMP) sprejel naslednje znanstvene zaključke:
Armisarte should not been used if there are any signs of particles.
Zdravila Armisarte ne uporabljajte, če v njem opazite delce.
Nadir platelets <50,000/mm 3 with bleedinga, regardless of nadir ANC
Najnižje število trombocitov < 50.000 /mm3 s krvavitvijoa, ne glede na najnižji ANC
Vials may or may not be sheathed in a protective sleeve.
Viala je lahko shranjena v zaščitni ovojnici.
- If you get any side effects, talk to your doctor or nurse or pharmacist.
- Če opazite kateri koli neželeni učinek se posvetujte z zdravnikom, medicinsko sestro ali farmacevtom.
You must take at least 5 doses during the seven days before the first dose of Armisarte.
V sedmih dneh pred prvim odmerkom zdravilom Armisarte morate vzeti vsaj 5 odmerkov.
Armisarte is provided in a colourless glass vial with rubber stopper and an aluminium cap with polypropylene disk.
Zdravilo Armisarte je na voljo v brezbarvni stekleni viali z gumijastim zamaškom in aluminijasto zaporko s polipropilensko ploščico.
The other ingredients are trometamol (for pH adjustment), anhydrous citric acid, methionine and water for injection.
Druge pomožne snovi so trometamol (za uravnavanje pH), brezvodna citronska kislina, metionin in voda za injekcije
Non-small cell lung cancer
Large Cell Carcinoma
There is no relevant use of pemetrexed in the paediatric population in malignant pleural mesothelioma and non-small cell lung cancer.
Pri pediatrični populaciji se pemetreksed ne uporablja za zdravljenje malignega plevralnega mezotelioma in nedrobnoceličnega karcinoma pljuč.